NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that its virtual-only Annual Meeting of Shareholders will be held on Tuesday, June 13, 2023, at 10:30 AM ET.
To participate in the Annual Shareholders Meeting, shareholders should visit https://east.virtualshareholdermeeting.com/vsm/web?pvskey=INKT2023 and enter the 16-digit control number found in their proxy materials. Guests may participate in a listen-only mode. No control number is required for guests.
Webcast Information:
Date: Tuesday June 13th, 2023
Time: 10:30 AM ET
A live webcast and replay will be accessible from the Company's website at https://investor.minktherapeutics.com/events-and-presentations and at https://east.virtualshareholdermeeting.com/vsm/web?pvskey=INKT2023.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/. Follow us on Twitter @MiNK_iNKT.
Contact
Alexa Buffa
781-674-4428
communications@minktherapeutics.com
Investor Relations:
Zack Armen
917-362-1370
investor@minktherapeutics.com
| Last Trade: | US$7.03 |
| Daily Change: | 0.11 1.58 |
| Daily Volume: | 4,672 |
| Market Cap: | US$278.600M |
March 18, 2025 February 24, 2025 February 12, 2025 January 23, 2025 December 18, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
